Founder Spotlight

MightyZebras™ Bio is developing the first targeted therapy for Hypermobile Ehlers-Danlos syndrome (hEDS), a debilitating connective tissue disorder affecting over 27 million people worldwide. With no approved disease-modifying treatments, patients face chronic pain, fatigue, and joint instability. Our breakthrough drug program targets the molecular pathways driving hEDS, supported by advanced delivery technologies and positioned for accelerated approval. Serving an initial market of approximately 67,000 specialist-managed patients across major regions (a $0.5 to $0.9 billion opportunity), MightyZebras™ Bio aims to transform care for the broader hEDS population and related disorders, addressing one of the largest unmet needs in rare disease with meaningful patient impact and scalable growth.

To learn more about Mighty Zebras or to Donate visit the website : https://www.mightyzebras.bio/about/